-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Entrada Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2025.
- Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$44.1M, a 215% decline year-over-year.
- Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$103M, a 288% decline year-over-year.
- Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $65.6M.
- Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$6.69M, a 92.9% increase from 2022.
- Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.6M, a 84.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)